Equities Analysts Offer Predictions for EW FY2025 Earnings

Key Points

• Zacks Research has increased its FY2025 earnings per share estimate for Edwards Lifesciences to $2.49, slightly above the previous estimate of $2.48.
• Edwards Lifesciences' stock has received several upgrades from analysts, with price targets ranging from $80 to $85 and a consensus rating of "Moderate Buy".
• In recent insider transactions, VP Daniel J. Lippis and insider Larry L. Wood sold shares of the company, indicating a decrease in their ownership stakes.

Edwards Lifesciences Corporation (NYSE:EW - Free Report) - Equities research analysts at Zacks Research upped their FY2025 earnings per share (EPS) estimates for Edwards Lifesciences in a note issued to investors on Friday, September 26th. Zacks Research analyst Team now anticipates that the medical research company will post earnings per share of $2.49 for the year, up from their previous forecast of $2.48. The consensus estimate for Edwards Lifesciences' current full-year earnings is $2.45 per share.

Several other equities research analysts also recently weighed in on the stock. Dbs Bank upgraded shares of Edwards Lifesciences to a "hold" rating in a report on Monday, June 2nd. Evercore ISI boosted their target price on Edwards Lifesciences from $77.00 to $80.00 and gave the company an "in-line" rating in a research report on Friday, July 25th. Canaccord Genuity Group increased their price target on Edwards Lifesciences from $75.00 to $81.00 and gave the stock a "hold" rating in a report on Friday, July 25th. Morgan Stanley boosted their price objective on Edwards Lifesciences from $75.00 to $81.00 and gave the company an "equal weight" rating in a report on Tuesday, July 15th. Finally, Stifel Nicolaus set a $85.00 target price on Edwards Lifesciences and gave the stock a "buy" rating in a report on Monday, September 22nd. Three investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $86.61.

Edwards Lifesciences Stock Up 1.4%

Edwards Lifesciences stock opened at $76.34 on Monday. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $44.82 billion, a PE ratio of 10.98, a PEG ratio of 3.67 and a beta of 1.07. The firm's fifty day moving average is $78.50 and its 200 day moving average is $75.78. Edwards Lifesciences has a 12-month low of $64.00 and a 12-month high of $83.00.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.62 by $0.05. The firm had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The company's revenue was up 11.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.70 earnings per share. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS.

Insiders Place Their Bets

In other news, VP Daniel J. Lippis sold 4,114 shares of the stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $79.46, for a total value of $326,898.44. Following the completion of the sale, the vice president owned 22,002 shares in the company, valued at $1,748,278.92. This represents a 15.75% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Larry L. Wood sold 8,950 shares of the firm's stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $78.06, for a total transaction of $698,637.00. Following the transaction, the insider directly owned 206,900 shares in the company, valued at $16,150,614. The trade was a 4.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.34% of the company's stock.

Hedge Funds Weigh In On Edwards Lifesciences

Hedge funds have recently modified their holdings of the company. Quantbot Technologies LP purchased a new stake in shares of Edwards Lifesciences during the first quarter valued at approximately $26,000. SouthState Corp bought a new position in Edwards Lifesciences in the 1st quarter valued at $27,000. Rosenberg Matthew Hamilton purchased a new stake in shares of Edwards Lifesciences during the 2nd quarter valued at $28,000. Global X Japan Co. Ltd. increased its position in shares of Edwards Lifesciences by 116.1% during the 1st quarter. Global X Japan Co. Ltd. now owns 402 shares of the medical research company's stock valued at $29,000 after purchasing an additional 216 shares during the last quarter. Finally, Tradewinds Capital Management LLC boosted its holdings in shares of Edwards Lifesciences by 102.5% in the 1st quarter. Tradewinds Capital Management LLC now owns 405 shares of the medical research company's stock worth $29,000 after buying an additional 205 shares during the last quarter. Institutional investors own 79.46% of the company's stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.